Simon ReadFounder

United States - Cambridge, Massachusetts

Simon is Founder, CEO and Board Member of Mariana Oncology (formerly Curie Therapeutics), a precision radiopharmaceutical company based in Boston (USA). He is also an Entrepreneur In Residence at Atlas Venture. Prior to his current roles, Simon was CSO at Ra Pharma (NASDAQ: RARX) until its acquisition by UCB Pharma in April 2020. Simon brings more than 25 years of R&D experience including leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech. Simon has worked on the clinical development of some of the most well-known drugs in the industry including Rituxan® and Actemra®. Simon is a Fellow of the Royal Society of Medicine, a Board Member of Triana Biomedicines, Scientific Advisory Board member of Q32 Bio and a member of the Boston Children’s Hospital Technology Development Fund. He obtained his Ph.D from University of Hertfordshire and studied Physiology at the University of Manchester in the UK. Simon is well published, having authored over 50 articles in peer reviewed journals and patents.